Pucotenlimab clinical trials
Also written HX008.
How each study uses pucotenlimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pucotenlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
51 studies that test it; most in 2026 (22); 1 more planned to start later
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 9 |
| 2026 | 22 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 38
Sun Yat-sen University (13) · Taizhou Hanzhong biomedical co. LTD (10) · Fudan University (4) · Shanghai Zhongshan Hospital (2) · Sir Run Run Shaw Hospital (2) · Lepu Biopharma Co., Ltd. (2) · Jiyan Liu (2) · Tongji Hospital (2)
Often tested with
Tested in the same studies.
Becotatug vedotin (21) · Lenvatinib (7) · Trastuzumab vedotin (2) · Donafenib (1) · Folfox protocol (1) · Trifluridine tipiracil drug combination (1) · CAPOX Regimen (1) · Xelox (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 14
Studies that test pucotenlimab.
- Dec 2026Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular CarcinomaPhase 2 · Sun Yat-sen University
- Dec 2026A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell CarcinomaPhase 2 · Lei Liu
- Dec 2026Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCCPhase 2 · Sun Yat-sen University
- Mar 2027Neoadjuvant Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)Phase 2 · Shanghai Zhongshan Hospital
- Mar 2027Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown PrimaryPhase 2 · Zhiguo Luo, MD, PhD
- Apr 2027Pucotenlimab Combined With Lenvatinib and Chemotherapy in the Treatment of Advanced, Relapsed/Refractory Hepatoblastoma in ChildrenNot applicable · Sun Yat-sen University
- Apr 2027Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction AdenocarcinomaEarly Phase 1 · Fujian Medical University
- Jun 2027Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell CarcinomaPhase 2 · Sun Yat-sen University
- Aug 2027A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid TumorsPhase 1/2 · Lepu Biopharma Co., Ltd.
- Aug 2027FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic CholangiocarcinomaPhase 2 · Sun Yat-sen University
Studies
Open first, then newest update. How each study uses pucotenlimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 52
- Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07922915Written as Pucotenlimab
- Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma With Suboptimal Response to Induction ImmunochemotherapyNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07915258Written as Pucotenlimab
- Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal CancerRecruitingPhase 2Fudan UniversityNCT07884188Written as Pucotenlimab
- Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07448142Written as Pucotenlimab
- A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile CancerRecruitingPhase 2Fudan UniversityNCT07497919Written as Becotatug Vedotin (recombinant humanized anti-EGFR mAb-MMAE conjugate) combined with Pucotenlimab (recombinant humanized anti-PD-1 mAb)
- A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Lepu Biopharma Co., Ltd.NCT05688605Written as MRG003+HX008
- A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal CarcinomaRecruitingPhase 3Lepu Biopharma Co., Ltd.NCT06976190Written as MRG003 + Pucotenlimab
- Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07766889Written as Pucotenlimab
- Neoadjuvant Pucotenlimab and Becotatug Vedotin for Locally Advanced Penile CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07767266Written as Pucotenlimab plus Becotatug Vedotin
- Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant MelanomaRecruitingPhase 2Sun Yat-sen UniversityNCT07750067Written as Pucotenlimab
- EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile CancerRecruitingPhase 2Jiyan LiuNCT07518979Written as Pucotenlimab
- Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic CholangiocarcinomaRecruitingPhase 2Tongji HospitalNCT06192797Written as Lenvatinib plus pucotenlimab
- Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-PositiveRecruitingPhase 2Tianjin Medical University Second HospitalNCT07712029Written as Pucotenlimab
- Neoadjuvant EGFR-ADC Combined With Anti-PD-1 Monoclonal Antibody in Resectable Locally Advanced Hypopharyngeal Squamous Cell CarcinomaRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07665190Written as Becotatug Vedotin and Pucotenlimab
- Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ AdenocarcinomaNot yet recruitingPhase 2West China Second University HospitalNCT07692334Written as Pucotenlimab
- Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase IINot yet recruitingPhase 2HuiKai LiNCT07649980Written as Pucotenlimab
- Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT07632339Written as Becotatug Vedotin combined with Pucotenlimab
- A Prospective, Single-arm, Phase II Clinical Trial of Becotatug Vedotin for Injection Combined With Pucotenlimab Injection as a First-line Treatment for Platinum-intolerant Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2Cancer Hospital Chinese Academy of Medical Science, Shenzhen CenterNCT07628855Written as Becotatug Vedotin (recombinant humanized anti-EGFR mAb-MMAE conjugate) combined with Pucotenlimab (recombinant humanized anti-PD-1 mAb)
- Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung CancerNot yet recruitingPhase 2Anhui Provincial Cancer HospitalNCT07627321Written as Pucotenlimab
- Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II StudyNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07589049Written as Pucotenlimab
See all 52 studies that test pucotenlimab →
Given beside what is tested · 10 — pucotenlimab is usual care or a partner of the new treatment
- Dynamic Plasma EBV DNA-Guided Risk-Adapted Treatment With Becotatug Vedotin (MRG003) Plus PD-1 Blockade in Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07524413Written as Pucotenlimab
- ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCCNot yet recruitingPhase 2Huashan HospitalNCT07844551Written as Pucotenlimab
- MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)RecruitingPhase 1/2Lepu Biopharma Co., Ltd.NCT07479485Written as Pucotenlimab
- A Prospective, Exploratory Study of Becotatug Vedotin Plus Putlimab for Neoadjuvant Therapy and Adjuvant Radiotherapy in Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2Jiangsu Cancer Institute & HospitalNCT07707167Written as Pucotenlimab
- Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell CarcinomaRecruitingPhase 2Lepu Biopharma Co., Ltd.NCT07586124Written as Pucotenlimab Injection
- Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR MutationsNot yet recruitingPhase 2/3Sir Run Run Shaw HospitalNCT07598318Written as Pucotenlimab
- Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and NeckRecruitingPhase 2Groupe Oncologie Radiotherapie Tete et CouNCT06959108Written as Pucotenlimab
- The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort StudyRecruitingPhase 2Ji DongmeiNCT07464366Written as Pucotenlimab
- A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and NeckCompletedPhase 2Lepu Biopharma Co., Ltd.NCT04868162Written as MRG003+HX008
- A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced MelanomaStatus unknownPhase 1Taizhou HoudeAoke Biomedical Co., Ltd.NCT04756934Written as HX008
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered3
- Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell CarcinomaNov 6, 2026NCT07922915
- Becotatug Vedotin Plus Pucotenlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma With Suboptimal Response to Induction ImmunochemotherapyNov 4, 2026NCT07915258
- Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal CancerOct 20, 2026NCT07884188
Codes
What other systems call pucotenlimab · ClinicalTrials.gg INT016225
- UNII (FDA) CGA81G3KR5PUCOTENLIMABOne source FDA
- NCI Thesaurus C160717PucotenlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | CGA81G3KR5 | PUCOTENLIMAB | One source FDA |
| NCI Thesaurus | C160717 | Pucotenlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.